Interaction of SR 33557 with skeletal muscle calcium channel blocker receptors in the baboon: characterization of its binding sites
- PMID: 1851830
Interaction of SR 33557 with skeletal muscle calcium channel blocker receptors in the baboon: characterization of its binding sites
Abstract
A procedure for the isolation of primate skeletal microsomal membranes was initiated. Membranes exhibited specific enzymatic markers such as 5'-nucleotidase, Ca++,Mg(++)-adenosine triphosphatase and an ATP-dependent calcium uptake. Baboon skeletal microsomes bound specifically with high-affinity potent Ca++ channel blockers such as dihydropyridine, phenylalkylamine and benzothiazepine derivatives. Scatchard analysis of equilibrium binding assays with [3H](+)-PN 200-110, [3H](-)-desmethoxyverapamil [( 3H](-)-D888) and [3H]-d-cis-dilitiazem were consistent with a single class of binding sites for the three radioligands. The pharmacological profile of SR 33557, an original compound with calcium antagonist properties, was investigated using radioligand binding studies. SR 33557 totally inhibited the specific binding of the three main classes of Ca++ channel effectors and interacted allosterically with them. In addition, SR 33557 bound with high affinity to a homogeneous population of binding sites in baboon skeletal muscle.
Similar articles
-
SR 33557, a novel calcium entry blocker. II. Interactions with 1,4-dihydropyridine, phenylalkylamine and benzothiazepine binding sites in rat heart sarcolemmal membranes.J Pharmacol Exp Ther. 1990 Nov;255(2):600-7. J Pharmacol Exp Ther. 1990. PMID: 2147036
-
SR33557, an indolizinsulfone blocker of Ca2+ channels: identification of receptor sites and analysis of its mode of action.Mol Pharmacol. 1989 Jun;35(6):766-73. Mol Pharmacol. 1989. PMID: 2543910
-
(-)-[3H] desmethoxyverapamil labels multiple calcium channel modulator receptors in brain and skeletal muscle membranes: differentiation by temperature and dihydropyridines.J Pharmacol Exp Ther. 1986 Jun;237(3):731-8. J Pharmacol Exp Ther. 1986. PMID: 3012067
-
SR 33557, a novel calcium-antagonist: interaction with [3H]-(+/-)-nitrendipine and [3H]-(-)-desmethoxy-verapamil binding sites in cerebral membranes.Naunyn Schmiedebergs Arch Pharmacol. 1989 Jan-Feb;339(1-2):31-6. doi: 10.1007/BF00165122. Naunyn Schmiedebergs Arch Pharmacol. 1989. PMID: 2542806
-
High-affinity binding of DTZ323, a novel derivative of diltiazem, to rabbit skeletal muscle L-type Ca++ channels.J Pharmacol Exp Ther. 1997 Apr;281(1):173-9. J Pharmacol Exp Ther. 1997. PMID: 9103495
Cited by
-
Inhibitory action of SR33557 on L-type calcium current in single ventricular myocytes of rat.Br J Pharmacol. 1995 Jan;114(2):468-74. doi: 10.1111/j.1476-5381.1995.tb13250.x. Br J Pharmacol. 1995. PMID: 7881746 Free PMC article.
-
Identification of a novel calcium antagonist binding site in rat brain by SR 33557.Br J Pharmacol. 1993 Jan;108(1):93-9. doi: 10.1111/j.1476-5381.1993.tb13445.x. Br J Pharmacol. 1993. PMID: 7679034 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials